Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
09:45am, Thursday, 13'th Mar 2025
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
12:50pm, Thursday, 27'th Feb 2025
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and su
Solid Growth, Soft Outlook: Why I'm Holding On Veracyte
10:32am, Tuesday, 25'th Feb 2025
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively w
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
09:00am, Tuesday, 25'th Feb 2025
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
10:53pm, Monday, 24'th Feb 2025
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Of
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
06:30pm, Monday, 24'th Feb 2025
Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago.
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Monday, 24'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of w
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
09:25am, Friday, 21'st Feb 2025
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Veracyte to Participate in Upcoming Investor Conferences
05:05pm, Wednesday, 19'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond Jam
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Res
Best Momentum Stocks to Buy for February 13th
11:01am, Thursday, 13'th Feb 2025
VCYT and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2025.
New Strong Buy Stocks for February 13th
05:56am, Thursday, 13'th Feb 2025
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
08:30am, Wednesday, 05'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer.
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
04:30pm, Tuesday, 04'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and ful
